Bronchiectasis and chronic obstructive pulmonary disease (COPD) share many pathophysiological, clinical and spirometric characteristics. Along with the increasing and widespread use of high resolution computed tomography (HRCT) scanning, bronchiectasis has become more detectable in patients presenting with chronic cough and shortness of breath. Identification of different phenotypes of COPD is important in terms of both therapeutic options and clinical outcomes of the disease. Co-occurrence of chronic obstructive pulmonary disease and bronchiectasis might be a different phenotype with more severe COPD and poorer prognosis. Many authors observed high prevalence of bronchiectasis in COPD patients showing association with increased inflammation, more severe and longer exacerbations, higher colonization of bronchial mucosa with potential pathogenic bacteria, and, the most important, with poorer prognosis
GOLD. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2013. (cited: 2013 March 30) Available from: URL: http://www.goldcopd.org.
Chonic obstructive pulmonary disease (COPD). (cited: 2013 April 4). Available from: URL: http://www.who.int/mediacentre/factsheets/fs315/ en/index.html.
Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-12. [CrossRef]
Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167: 544-9. [CrossRef]
Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: find- ings from the Copenhagen city heart study. Am J Respir Crit Care Med 2006; 173: 79-83. [CrossRef]
Domingo-Salvany A, Lamarca R, Ferrer M, Garcia-Aymerich J, Alonso J, Felez M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 680-5. [CrossRef]
Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidi- ties in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 549-55. [CrossRef]
Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-31. [CrossRef]
Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 250-5. [CrossRef]
Weycker D, Edelsberg J. Oster G, Tino G. Prevalence and economic bur- den of bronchiectasis. Clin Pulm Med 2005; 205-9.
Novosad SA, Barker AF. Chronic obstructive pulmonary disease and bronchiectasis. Curr Opin Pulm Med 2013; 19: 133-9. [CrossRef]
Martinez-Garcia MA, Soler-Cataluna JJ, Donat Sanz Y, Catalan Serra P, Agramunt Lerma M, Ballestin Vicente J, et al. Factors associated with bron- chiectasis in patients with COPD. Chest 2011; 140: 1130-7. [CrossRef]
Martinez-Garcia MA, de la Rosa D, Soler-Cataluna JJ, Donat-Sanz Y, Cata- lan Serra P, Agramunt Lerma M, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary dis- ease. Am J Respir Crit Care Med 2013; 187: 823-31. [CrossRef]
O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmo- nary disease in primary care. Thorax 2000; 55: 635-42. [CrossRef]
Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, et al. Bronchiectasis, exacerbation indices, and inflammation in chron- ic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 400-7. [CrossRef]
Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604. [CrossRef]
Silverman EK. Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression? Proc Am Thorac Soc 2007; 4: 586-90. [CrossRef]
Niewoehner DE, Collins D, Erbland ML. Relation of FEV(1) to clinical out- comes during exacerbations of chronic obstructive pulmonary disease. Department of veterans affairs cooperative study group. Am J Respir Crit Care Med 2000; 161: 1201-5. [CrossRef]
Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, et al. Evaluation of COPD longitudinally to identify predictive surrogate end- points (ECLIPSE). Eur Respir J 2008; 31: 869-73. [CrossRef]
Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of flu- ticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008; 102: 1099-108. [CrossRef]
Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-94. [CrossRef]
Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, et al. A ran- domized trial comparing lung-volume-reduction surgery with medical ther- apy for severe emphysema. N Engl J Med 2003; 348: 2059-73. [CrossRef]
Tulek B, Kivrak AS, Ozbek S, Kanat F, Suerdem M. Phenotyping of chronic obstructive pulmonary disease using the modified Bhalla scoring system gor high-resolution computed tomography. Can Respir J 2013; 20: 91-6.
Garcia-Vidal C, Almagro P, Romani V, Rodriguez-Carballeira M, Cuchi E, Canales L, et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J 2009; 34: 1072-8. [CrossRef]
Martinez-Solano L, Macia MD, Fajardo A, Oliver A, Martinez JL. Chronic pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis 2008; 47: 1526-33. [CrossRef]
Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest 2012; 122: 2749-55. [CrossRef]
Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2007; 176: 1215-21. [CrossRef]
Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease? Heart Lung 2006; 35: 58-65. [CrossRef]